Skip to main content
. 2018 Feb 2;36(5):591–601. doi: 10.1007/s40273-017-0604-3

Fig. 3.

Fig. 3

Cost-effectiveness acceptability frontier for genotype 2. PEG peginterferon-α-2a, RBV ribavirin, SOF sofosbuvir, QALY quality-adjusted life-year